


FIG. 1



40%
0%
RELATIVE INTENSITY
1502
1486
1664
1648
MASS (m/z)

FIG.2A



30%
0%
RELATIVE INTENSITY
1486
1502
1648
1664
1257
1810
MASS (m/z)

FIG.2B



20%
0%
RELATIVE INTENSITY
1502
1486
1664
1648
1705
1689
1867
1851
1273
1257
1810
MASS (m/z)

FIG.2C



20%
0%
RELATIVE INTENSITY
1851
1486
1664
1689
1867
1502
1705
1648
1257
1273
1810
MASS (m/z)

FIG.2D



20%
0%
RELATIVE INTENSITY
1257
1273
1486
1502
1648
1664
1680
1689
1705
1810
1826
1851
1867
1972
1988
MASS (m/z)

FIG.2E



G—Gn—M
Gn—M—Gn—Gn—Asn
F
G—Gn—M
CORE

FIG.3A



M9 1906
3X ManI
M6 1420
ManI
M5 1257
GnTI
HYBRID BISECTED
1462–f
1607+f
M5Gn
GnTIII
1664–f
1810+f
M5GnGnb
GalT
1826–f
1972+f
M5GnGnbG
ManII
1298–f
1445+f
M4Gn
GnTIII
1502–f
1648+f
M4GnGnb
GalT
1664–f
1810+f
M4GnGnbG
ManII
1134–f
1281+f
M3Gn
GnTIII
1339–f
1486+f
M3GnGnb
GalT
1502–f
1648+f
M3GnGnbG
GnTII
1502–f
1647+f
M3Gn2G
GalT
M3Gn2
GnTIII
1339–f
1486+f
M3Gn2Gnb
GalT
1705–f
1851+f
M3Gn2GnbG
GalT
1543–f
1689+f
GalT
M3Gn2G2
1664–f
1810+f
M3Gn2GnbG2
1867–f
2013+f
COMPLEX
COMPLEX BISECTED

FIG.3B



C2B8-25t
C2B8-50t
C2B8-2000t
C2B8-nt
% CYTOTOXICITY
60
50
40
30
20
10
0.01
0.1
1
10
mAb (MICROGRAM/mL)

FIG.4A



C2B8-25t
C2B8-50t
MabThera (TM)
% CYTOTOXICITY
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
mAb (MICROGRAM/mL)

FIG.4B




FIG.5




FIG.6



3.6E+4
WT
1648
1486
1502
1321
1664
1810
1973
% INTENSITY
MASS (m/z)
0
10
20
30
40
50
60
70
80
90
100
1200
1400
1600
1800
2000
2200

FIG.7A



1.4E+4
2F1
1664
1648
1689
1705
1810
1826
1851
1973
1989
1257
1339
1420
1486
1502
1543
% INTENSITY
MASS (m/z)
0
10
20
30
40
50
60
70
80
90
100
1200
1400
1600
1800
2000
2200

FIG.7B



9.8E+3
3D3
1257
1420
1486
1502
1648
1664
1680
1689
1705
1810
1826
1851
1867
1973
1989
100
90
80
70
60
50
40
30
20
10
0
1200
1400
1600
1800
2000
2200
MASS (m/z)
% INTENSITY

FIG.7C



2.5E+4
4E6
1257
1420
1502
1543
1648
1664
1689
1705
1810
1826
1851
1973
1989
100
90
80
70
60
50
40
30
20
10
0
1200
1400
1600
1800
2000
2200
MASS (m/z)
% INTENSITY

FIG.7D



3.3E+4
4E8
1257
1339
1420
1486
1502
1543
1648
1664
1680
1689
1705
1810
1826
1851
1973
1989
100
90
80
70
60
50
40
30
20
10
0
1200
1400
1600
1800
2000
2200
0
% INTENSITY
MASS (m/z)

FIG.8A



1.8E+4
5G2
1257
1420
1486
1502
1543
1648
1664
1689
1705
1810
1826
1851
1973
1989
100
90
80
70
60
50
40
30
20
10
0
1200
1400
1600
1800
2000
2200
0
% INTENSITY
MASS (m/z)

FIG.8B



2.5E+4
0
4G3
1257
1420
1486
1502
1543
1648
1664
1689
1705
1810
1851
1826
1973
1989
2014
1200
1400
1600
1800
2000
2200
MASS (m/z)
% INTENSITY
100
90
80
70
60
50
40
30
20
10
0

FIG.8C



2.1E+4
0
5H12
1257
1273
1502
1648
1664
1680
1705
1721
1810
1826
1842
1851
1867
1973
1989
1200
1400
1600
1800
2000
2200
MASS (m/z)
% INTENSITY
100
90
80
70
60
50
40
30
20
10
0

FIG.8D



IN VITRO ADCC ACTIVITY OF NEW ENGINEERED chG250 mAb
CONTROL
3D3
5H12
% CYTOTOXICITY
80
60
40
20
0
-20
0.01
0.1
1
10
mAb CONC. (μg/mL)

FIG.9